Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects
Phase 1
Completed
- Conditions
- Coronavirus Disease 2019(COVID-19)
- Interventions
- Other: PlaceboBiological: SCTA01
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 33
- Registration Number
- NCT04483375
- Locations
- 🇨🇳
Beijing SHIJITAN Hospital, Beijing, Beijing, China
Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC
Phase 1
- Conditions
- Esophageal Squamous Cell CarcinomaColorectal Cancer
- Interventions
- Biological: SCT-I10ABiological: SCT200Other: Chemotherapy
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04229537
SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer
Phase 3
Terminated
- Conditions
- Squamous-cell Non-Small-cell Lung Cancer
- Interventions
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 188
- Registration Number
- NCT04171284
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
Phase 3
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Drug: Placebos+chemoDrug: SCT-I10A+chemo
- First Posted Date
- 2019-10-31
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 330
- Registration Number
- NCT04146402
- Locations
- 🇨🇳
The Third Affiliated Hospital Of Qiqihar Medical University, Qiqihar, China
Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma
Phase 2
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Drug: PD-1
- First Posted Date
- 2019-10-31
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 103
- Registration Number
- NCT04146181
- Locations
- 🇨🇳
Guangxi Medical University Affiliated Tumour Hospital, Nanning, Guangxi, China
Safety,Efficacy and Pharmacokinetics Evaluation of SCT800 in Previously Treated Paediatric Patients With Severe Haemophilia A.
Phase 3
- Conditions
- Hemophilia A
- Interventions
- Drug: Recombinant Human Coagulation FVIII
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2019-05-13
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT03947320
Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.
Phase 4
Recruiting
- Conditions
- Hemophilia A
- Interventions
- Drug: Recombinant Human Coagulation FVIII
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT03947567
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
Phase 3
- Conditions
- Psoriasis
- Interventions
- Biological: AdalimumabBiological: SCT630
- First Posted Date
- 2019-04-25
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 330
- Registration Number
- NCT03927352
- Locations
- 🇨🇳
First Affiliated Hospital of Fourth Military Medical University, Xi'an, Shaanxi, China
Pharmacokinetics and Safety in Healthy Volunteers
- First Posted Date
- 2019-04-17
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 146
- Registration Number
- NCT03917628
- Locations
- 🇨🇳
Beijing SHIJITAN Hospital, Beijing, Beijing, China
SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell Carcinoma
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2020-05-27
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT03874741
- Locations
- 🇨🇳
Cancer hospital Chinese academy of medical sciences, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath